ClinicalTrials.gg
CompletedNCT00449930Updated May 11, 2017Results posted

Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)

A Phase 3 interventional study of sitagliptin phosphate and Comparator: metformin hydrochloride in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-11.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,050
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
10th of 197
1,050 · median 102
Started
2007
with 16 others
Phase 3
74 of 198
none open now
Registered
24th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 74 in phase 3, and was the 24th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A study to evaluate the efficacy and safety of sitagliptin in comparison to a commonly used medication in patients with type 2 diabetes

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria:

  • Patient has type 2 diabetes mellitus (T2DM)
  • Patient is inadequately controlled and not on treatment with insulin or oral antihyperglycemic therapy

General Exclusion Criteria:

  • Patient has a history of type 1 diabetes mellitus or history of ketoacidosis
  • Patient was on antihyperglycemic therapy (insulin or oral) within the prior 4 months
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,050 participants (actual)

Study arms

  • Experimental
    1

    Drug

    Drug: sitagliptin phosphate

  • Active comparator
    2

    Active comparator

    Drug: Comparator: metformin hydrochloride

Interventions

  • DrugSitagliptinStudies of SitagliptinSitagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    (1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period

    Also known as: MK0431

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    (4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24

    HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.

    Time frame: Baseline and 24 weeks

Secondary outcomes

  1. Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Diarrhea

    Time frame: Baseline to Week 24

  2. Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Nausea

    Time frame: Baseline to Week 24

  3. Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Abdominal Pain

    Time frame: Baseline to Week 24

  4. Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Vomiting

    Time frame: Baseline to Week 24

07

Results

Posted Aug 11, 2009
Limitations and caveats
Site 0490125 was non-compliant with Good Clinical Practice (GCP). Data from the 8 patients at this site were removed from all analyses.

Participant flow

First patient In: 04-Apr-2007 Last Patient Last Visit: 25-Jul-2008 113 study centers worldwide

Participant flow — Overall Study
MilestoneSitagliptin 100 mgMetformin
Started528522
Completed467447
Not completed6175
Withdrew: Adverse event919
Withdrew: Trial terminated ( site closed)10
Withdrew: Lack of efficacy101
Withdrew: Lost to follow-up914
Withdrew: Physician decision12
Withdrew: Protocol violation1415
Withdrew: Withdrawal by subject1623
Withdrew: Glycemic discontinuation criteria11

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c) at Week 24

HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.

Time frame:
Baseline and 24 weeks
Reported as:
Least squares mean · Percent
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24
PercentSitagliptin 100 mgMetformin
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24-0.43 (-0.48 to -0.38)-0.57 (-0.62 to -0.51)
Statistical analysis
  • Sitagliptin 100 mg vs Metformin · Mean difference (net): 0.14 · 95% CI 0.06 to 0.21Based on an analysis of covariance (ANCOVA) model with terms for treatment group and baseline value.
SecondaryNumber of Patients Who Reported 1 or More Episodes of the Adverse Experience of Diarrhea
Time frame:
Baseline to Week 24
Reported as:
Number · Participants
Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Diarrhea
ParticipantsSitagliptin 100 mgMetformin
Patients Who Reported Diarrhea1957
Patients Who Did Not Report Diarrhea509465
Statistical analysis
  • Sitagliptin 100 mg vs Metformin · Fisher Exact · p = <0.001 · Risk difference (rd): -7.3 · 95% CI -10.6 to -4.2Difference (sitagliptin minus metformin) in the percentage of patients with diarrhea. Wilson Score method was used for the 95% Confidence Interval (CI).
SecondaryNumber of Patients Who Reported 1 or More Episodes of the Adverse Experience of Nausea
Time frame:
Baseline to Week 24
Reported as:
Number · Participants
Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Nausea
ParticipantsSitagliptin 100 mgMetformin
Patients Who Reported Nausea616
Patients Who Did Not Report Nausea522506
Statistical analysis
  • Sitagliptin 100 mg vs Metformin · Fisher Exact · p = 0.032 · Risk difference (rd): -1.9 · 95% CI -3.9 to -0.2Difference (sitagliptin minus metformin) in the percentage of patients with nausea. Wilson Score method was used for the 95% CI.
SecondaryNumber of Patients Who Reported 1 or More Episodes of the Adverse Experience of Abdominal Pain
Time frame:
Baseline to Week 24
Reported as:
Number · Participants
Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Abdominal Pain
ParticipantsSitagliptin 100 mgMetformin
Patients Who Reported Abdominal Pain1120
Patients Who Did Not Report Abdominal Pain517502
Statistical analysis
  • Sitagliptin 100 mg vs Metformin · Fisher Exact · p = 0.103 · Risk difference (rd): -1.7 · 95% CI -4.0 to 0.3Difference (sitagliptin minus metformin) in the percentage of patients with abdominal pain. Wilson Score method was used for the 95% CI.
SecondaryNumber of Patients Who Reported 1 or More Episodes of the Adverse Experience of Vomiting
Time frame:
Baseline to Week 24
Reported as:
Number · Participants
Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Vomiting
ParticipantsSitagliptin 100 mgMetformin
Patients Who Reported Vomiting27
Patients Who Did Not Report Vomiting526515
Statistical analysis
  • Sitagliptin 100 mg vs Metformin · Risk difference (rd): -1.0 · 95% CI -2.4 to 0.2Difference (sitagliptin minus metformin) in the percentage of patients with vomiting. Wilson Score method was used for the 95% CI.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 100 mg———
Metformin———
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventSitagliptin 100 mgMetformin
Any Cardiac disordersCardiac disorders1/5283/522
Any Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications3/5280/522
Any Infections and infestationsInfections and infestations2/5282/522
Acute myocardial infarctionCardiac disorders0/5281/522
Coronary artery diseaseCardiac disorders0/5281/522
TachyarrhythmiaCardiac disorders0/5281/522
Any Congenital, familial and genetic disordersCongenital, familial and genetic disorders0/5281/522
Multiple endocrine adenomatosis Type IICongenital, familial and genetic disorders0/5281/522
Any General disorders and administration site conditionsGeneral disorders0/5281/522
Non-cardiac chest painGeneral disorders0/5281/522
Most frequent other events
Most frequent other events
EventSitagliptin 100 mgMetformin
Any Gastrointestinal disordersGastrointestinal disorders19/52857/522
DiarrhoeaGastrointestinal disorders19/52857/522

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sitagliptin 100 mgMetforminTotal
Mean55.9 ± 10.756.1 ± 10.456.0 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin 100 mgMetforminTotal
Female278288566
Male250234484
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Sitagliptin 100 mgMetforminTotal
White397395792
Black241943
Asian6462126
Other434689
Body Weight
Body Weight(Kilograms)Sitagliptin 100 mgMetforminTotal
Mean84.9 ± 17.784.6 ± 17.284.7 ± 17.5
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(Percent)Sitagliptin 100 mgMetforminTotal
Mean7.2 ± 0.77.3 ± 0.77.3 ± 0.7
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, Goldstein BJ; Sitagliptin Study 049 Group. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2010 Mar;12(3):252-61. doi: 10.1111/j.1463-1326.2009.01187.x. Epub 2009 Nov 25. PubMed 20070351 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2007 to primary completion in Jul 2008, 16 months.

Results were first posted in Aug 2009, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2007
First posted
Mar 21, 2007
StartActual
Mar 1, 2007
Primary completionActual
Jul 25, 2008
CompletionActual
Jul 25, 2008
Results first posted
Aug 11, 2009
Last update
May 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00449930
Responsible party
Sponsor
First posted
Mar 21, 2007
Start date
Mar 1, 2007
Primary completion
Jul 25, 2008
Completion
Jul 25, 2008
Results posted
Aug 11, 2009
Last update
May 11, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion